SRX Global Provides Shareholders with Update on Liquidation of Two Portfolio Investments and Adds an Investment in Onconetix (Nasdaq: ONCO)

What SRX announced

SRX Global issued a statement to shareholders reporting an update on the liquidation of two portfolio holdings and disclosing a new investment in Onconetix Inc. The company framed the Onconetix investment in the context of Onconetix’s previously announced agreement to acquire Realbotix LLC.

Sources: S1

Portfolio liquidations reported

SRX said it was providing shareholders with an update on the liquidation of holdings in Vistagen Therapeutics (Nasdaq: VTGN) and Greenland Mines (Nasdaq: GRML). The company presented this as part of portfolio activity and repositioning.

Sources: S1

New investment and technology description

SRX reported adding ONCO in anticipation of the Realbotix LLC acquisition closing and described Realbotix’s Vinci AI Vision System and in-eye sensor approach. The release outlines Vinci’s capabilities including motion detection, user recognition, object and color identification, and analysis of micro-expressions to adapt robot conversation through integrated large language models (LLMs). SRX also stated it believes the Vinci system is undervalued and sees potential applications in defense.

Sources: S1

Context and company positioning

The release identifies SRX Global as an AI-driven platform focused on investments intended to generate long-term shareholder value, and it includes standard forward-looking statements language noting risks and uncertainties and that forward-looking statements speak only as of the date made.

Sources: S1

What remains uncertain

• All descriptions of the Vinci AI Vision System, the value SRX attaches to it, and the anticipated benefits of the Onconetix investment are company statements from the press release and have not been independently verified in this draft.
• The release contains forward-looking statements regarding the completion, timing and potential benefits of Onconetix’s pending acquisition of Realbotix LLC; those outcomes are subject to risks and uncertainties as stated by the company.
• The announcement reports liquidation activity but does not provide transaction terms, proceeds, or timing details for the holdings in Vistagen Therapeutics (Nasdaq: VTGN) or Greenland Mines (Nasdaq: GRML).